VEXIM received regulatory approval from ANVISA to commercialize SpineJack® in Brazil for the treatment of vertebral compression fractures (VCFs).
VEXIM estimates that Brazil’s VCF treatment market is valued at €15MM (~US $17MM). Export of SpineJack devices to the region will commence in coming months, following the product’s evaluation process and establishment of distribution partnerships.
The SpineJack portfolio comprises three titanium implants of differing diameters that address 95% of VCFs and all patient morphologies.
VEXIM received regulatory approval from ANVISA to commercialize SpineJack® in Brazil for the treatment of vertebral compression fractures (VCFs).
VEXIM estimates that Brazil's VCF treatment market is valued at €15MM (~US $17MM). Export of SpineJack devices to the region will commence in coming months, following the product’s evaluation process...
VEXIM received regulatory approval from ANVISA to commercialize SpineJack® in Brazil for the treatment of vertebral compression fractures (VCFs).
VEXIM estimates that Brazil’s VCF treatment market is valued at €15MM (~US $17MM). Export of SpineJack devices to the region will commence in coming months, following the product’s evaluation process and establishment of distribution partnerships.
The SpineJack portfolio comprises three titanium implants of differing diameters that address 95% of VCFs and all patient morphologies.
Copy to clipboard 
